Bringing you your weekly update on the impact of COVID 19 on blood cancer patients and carers. The key take home messages are: Keep up your social distancing it is hard but it is working
Hear from Prof Miles Prince as he provides an update on the impact of the Coronavirus on the management of your blood cancer. His top tips were: • Get the flu shot it is available
Snowdome Foundation took the opportunity to film Prof Miles Prince AM as he spoke about his advice to blood cancer patients during COVID 19. We hope you find this video useful and reassuring. Please click
We are proud to share with you the Snowdome Foundation 2019 Annual Review. The review celebrates 10 years of ‘making hope real’ for Australian blood cancer patients. We hope you are just as proud of
18 months ago Snowdome spoke with Amanda Lindell while she was in the middle of treatment for her chronic lymphocytic leukaemia (CLL). CLL generally affects people 20 years older than Amanda and is usually a
Professor Ricky Johnstone is the Head of the Gene Regulation Laboratory at the Peter MacCallum Cancer Centre and the Head, The Sir Peter MacCallum Department of Oncology, The University of Melbourne. He is the recipient
Wonderful to see the FDA, TGA and Canadian regulatory authorities working together to approve a new treatment for refractory/ relapsed Chronic Lymphocytic Leukaemia (CLL). Acalabrutinib is a second-generation BTK (Bruton’s tyrosine kinase or tyrosine-protein kinase)
Andrea grew up in Melbourne and has over 20 years experience in senior leadership positions working with organisations like Nike Australia. Andrea relocated to WA with her family and currently manages the WA Chapter of
Kaz should have been snuggling into her newborn baby, gazing into her eyes as she fed but instead, she was being infused with chemotherapy. A substance so toxic she couldn’t even hold her beautiful baby
In a very short period of time Blood Cancer Research WA, supported by the Snowdome Foundation, has managed to increase the number of blood cancer patients on clinical trials by almost 100 and reduce the
